A Study of LY3361237 in Participants With Psoriasis

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04975295

Enrollment

Registered

2021-07-23

Start date

2021-07-27

Completion date

2022-11-29

Last updated

2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.

Interventions

DRUGLY3361237

Administered SC

DRUGPlacebo

Administered SC

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Have chronic plaque psoriasis for at least 6 months * Be willing and able to undergo skin biopsies * Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²) * Female participants must agree to use birth control during the study

Exclusion criteria

* Have had certain types of infection within the last six months * Have a clinically significant active infection, or recent acute active infection within the last 30 days * Have other serious or unstable illnesses * Have a history of organ or bone marrow transplant * Have received any live vaccine within the last 4 weeks prior to screening * Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1 * Have received topical psoriasis treatment within 14 days prior to study day 1 * Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Baseline through Day 253	A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary

Measure	Time frame	Description
Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of LY3361237 During the Dosing Interval	Day 1 predose through Day 253	PK: Cmin of LY3361237 During the Dosing Interval

Countries

Bulgaria, Hungary, Poland, Slovakia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026